News-United Well Technologies Limited

Language

EN CN

Home · News & Events

Industry Information

New PET tracer show promise in neuroblastoma

Molecular Targeting Technologies Presents First Clinical Validation of the Evans Blue Platform, Demonstrating Up to 15-Day Tumor Retention Using Approximately 12.5% of the Radioactivity Required for Conventional PRRT

Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform

New approach could expand CAR T therapy from blood cancers to solid tumors

PET/MRI can reduce the need for biopsies in prostate cancer

Production problems hamper Lantheus bid for FDA approval of radiopharma dx kit

1 2 3 4 5 6 7 ...